ZOU Lily 邹丽晖

Dr. Lily Zou

  • Co-founder and CEO, Degron Therapeutics

Lily Zou is co-founder and CEO of Degron Therapeutics, a biotech company focused on the discovery and development of innovative molecular glue degrader drugs for novel disease targets utilizing it proprietary technology platform. Prior to Degron, Lily was CEO of Fosun Pharma USA and VP of Fosun Pharma Group, where she built and grew Fosun Pharma’s US business with R&D, commercial and investment capabilities, and served as chairman or member of the board of four Fosun portfolio companies. Lily worked at top management consulting firm (Bain & Co.), large pharmas (Novartis, Wyeth, Fosun), and smaller biotechs (ArQule, Coley Pharmaceutical Group) in various functions including BD&L, R&D management, drug discovery, and commercialization.

Lily holds a Ph.D. in Microbiology and Immunology from Cornell University, an MBA from MIT, and a B.S. in Biology from Beijing University.